Obermatt
See Similar Stocks →

Flags

Financial distress

Gossamer Bio

NSQ:GOSS · US38341P1021
BiotechnologySmall

360

24
Profit price10
Owner Earnings Yield1
Dividend Yield1
Price/Sales88
EV / Gross Profit72
Price/Book67
Returns on capital18
Profit margins83
Accruals95
Owner Earnings Margin48
Sales growth23
Profit growth54
Reinvestment1
Price momentum1
Debt load1
Refinancing1
Debt Payback1
Liquidity53
Analyst ratings5
Expectations trend7
Market mood24
Value Creation7/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Gossamer Bio clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2015
Employees174
Websitegossamerbio.com
ISINUS38341P1021
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
CardiovascularPulmonologyRespiratoryBiotechnologyHealth CareTherapeutics

Description

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension, or PH, including pulmonary arterial hypertension, or PAH, and PH associated…

Analysis

Middle-of-the-road

Gossamer Bio, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 7/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

All-time high

8

Mar 2026

All-time low

1

Jun 2026

Average rank

5

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
88
—
—
—
Price/Earnings
12
—
—
—
Price/Book
67
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
73
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Gossamer Bio with its peers
United Therapeutics
NSQ:UTHR
76
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
MannKind
NMQ:MNKD
24
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Sellas Life Sciences
NAQ:SLS
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Olema Pharmaceuticals
NSQ:OLMA
28
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Celcuity
NAQ:CELC
96
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Inhibikase Therapeutics
NAQ:IKT
10
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →